Results 171 to 180 of about 131,644 (347)

Herbal medicines in functional dyspepsia—Untapped opportunities not without risks [PDF]

open access: hybrid, 2020
Kok‐Ann Gwee   +11 more
openalex   +1 more source

Dyspepsia

open access: yesInternational Journal of Clinical Practice, 1953
openaire   +2 more sources

Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 1, Page 132-144, January 2026.
In East Asian patients with chronic hepatitis B, rates of virologic suppression through 5 years were high in those treated continuously with tenofovir alafenamide (TAF) and in those switched from tenofovir disoproxil fumarate (TDF) to TAF. Improved renal and bone safety was observed in patients switching from TDF to TAF.
Grace Lai‐Hung Wong   +15 more
wiley   +1 more source

Epidemiology of dyspepsia and esophagogastroduodenoscopic findings in the era of <i>Helicobacter pylori</i> eradication. [PDF]

open access: yesWorld J Gastroenterol
Suzuki S   +12 more
europepmc   +1 more source

Predictive Value of Neutrophil/lymphocyte Ratio for Differentiating Organic Dyspepsia from Functional Dyspepsia [PDF]

open access: bronze, 2016
Hüseyin Köseoğlu   +7 more
openalex   +1 more source

Assessing Condition‐Specific Adverse Event Profiles of Modafinil for Labelled and Off‐Label Uses: A Systematic Review and Meta‐Analysis

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 138, Issue 1, January 2026.
ABSTRACT Modafinil is approved for excessive daytime sleepiness in narcolepsy, obstructive sleep apnoea (OSA), and shift work sleep disorder (SWSD), but its widespread off‐label use raises safety concerns. We evaluated the risk of adverse events (AEs) associated with both labelled and off‐label use of modafinil.
Jaehee Jung   +5 more
wiley   +1 more source

Pathophysiological mechanisms of functional dyspepsia: a narrative review. [PDF]

open access: yesFront Med (Lausanne)
Wang L   +5 more
europepmc   +1 more source

Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 728-740, January 2026.
Abstract Aims This study aimed to evaluate the efficacy and safety of triple therapy with lobeglitazone 0.5 mg as an add‐on treatment compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin.
Da Hea Seo   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy